Literature DB >> 2175177

Adrenal pheochromocytoma PC12h cells respond to pituitary adenylate cyclase activating polypeptide.

T Watanabe1, T Ohtaki, C Kitada, M Tsuda, M Fujino.   

Abstract

An adrenal pheochromocytoma cell line, PC12h, was found to respond to a novel hypothalamic neuropeptide, Pituitary Adenylate Cyclase Activating Polypeptide (PACAP). The cells elevated both intracellular and extracellular cAMP levels on stimulation by PACAP, whereas they showed little response to VIP which is structurally related to PACAP. Using [125I]PACAP27 (a shorter form of the peptide) and [125I]VIP, we found large amounts of specific binding sites for PACAP but few binding sites for VIP in PC12h cells. These results indicate that PC12h cells respond to PACAP via a specific PACAP receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2175177     DOI: 10.1016/s0006-291x(05)81049-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Pituitary adenylate cyclase activating polypeptide (PACAP) regulates expression of catecholamine biosynthetic enzyme genes in bovine adrenal chromaffin cells.

Authors:  C Tönshoff; L Hemmick; M J Evinger
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

2.  Molecular cloning and characterization of two pig vasoactive intestinal polypeptide receptors (VPAC1-R and VPAC2-R).

Authors:  Xiaping He; Fengyan Meng; Yajun Wang; Juan Li
Journal:  DNA Cell Biol       Date:  2014-02-12       Impact factor: 3.311

3.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

Authors:  J R Pisegna; S A Wank
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

4.  Regulation of gene expression in PC12 cells via an activator of dual second messengers: pituitary adenylate cyclase activating polypeptide.

Authors:  V C Schadlow; N Barzilai; P J Deutsch
Journal:  Mol Biol Cell       Date:  1992-08       Impact factor: 4.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.